Corcept Therapeutics Inc (CORT) Company Profile & Statistics

Corcept Therapeutics Inc
CORT
(Nasdaq - US)
Closed
55.92
-0.17 (-0.30%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
56.36
High
57.05
Low
55.41

About Corcept Therapeutics Inc

CEO

Joseph K. Belanoff

Headquarters

149 commonwealth drive

menlo park, ca 94025, united states

Auditor

Ernst & Young LLP

Employees

352

Share Holders

379

Website

www.corcept.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Corcept Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	5.86B
Enterprise Value	5.73B
Enterprise Value/EBITDA (ttm)	42.31
Price to Earnings Ratio (ttm)	43.10
Price to Book (mrq)	8.91
Price to Sales (ttm)	9.05
Price to Cash (ytd)	56.70

Profitability

Gross Margin (ttm)	98.44%
Operating Margin (ttm)	22.35%
Profit Margin (ttm)	22.19%
Return on Equity (ttm)	24.54%
Return on Invested Capital (ttm)	24.52%
Return on Assets (ttm)	20.24%

Income Statement

Revenue (ttm)	628.55M
Revenue Per Share (ttm)	6.00
Gross Profit (ttm)	618.75M
EBITDA (ttm)³	135.38M
Net Income Avi to Common (ttm)	140.49M
Diluted EPS (ttm)	1.26

Share Statistics

Beta (5Y Monthly)	0.45
52-Week Change	115.57%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	104.78M
Dividend Yield	0.00%
Float ⁴	83.30M
% Held by Insiders	20.50%
% Held by Institutions	93.61%

Balance Sheet

Total Cash (mrq)	380.34M
Total Cash Per Share (mrq)	3.63
Total Debt (mrq)	6.36M
Total Debt/Equity (mrq)	1.00%
Current Ratio (mrq)	3.70%
Quick Ratio (mrq)	3.64%
Book Value Per Share (mrq)	6.10

Cash Flow

Operating Cash Flow Per Share (ytd)	1.22
Free Cash Flow (ytd)	136.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Corcept Therapeutics Inc

Trade With A Regulated Broker